Tirzepatide (15mg Vial)
US$ 22.44
retatrutide type 2 diabetes phase 2 trial results 2024 Lilly's triple agonist achieves 16.8% weight loss in 3 Phase III retatrutide study demonstrates
Description
doi: 10.1002/hep.29367 184 BramanteCTignanelliCJDuttaNJonesETamarizLClarkJMet al
doi:10.1111/febs.14332 164
Keep reading for more details
See our [retatrutide dosing protocol](/guides/retatrutide-dosing-protocol-complete-titration-guide) for details on each dose level
HBI, HarveyBradshaw Index
With a fatty-acyl moiety on the GLP-1 peptide backbone, it has an increased half-life as a result of DPP-4 resistance and non-covalent binding to serum albumin
